Artiva Biotherapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fred Aslan
- Full Time Employees
- 115
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5505 Morehouse Drive San Diego CA United States of America 92121
- IPO Date
- Jul 19, 2024
- CIK
- 0001817241
- Website
- artivabio.com
- Similar Companies
- Business
- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company focused on developing cell therapies for patients with autoimmune diseases and chronic conditions. The company engineers allogeneic, off-the-shelf NK cell therapies, including its lead candidate AB-101, a non-genetically modified NK cell product designed to target and deplete autoreactive B cells; AB-201, an NK cell therapy engineered with a chimeric receptor targeting CD19 and CD20 antigens; and its CAR-NK pipeline targeting BCMA and GPRC5D for autoimmune and oncology indications. Artiva's platform leverages proprietary manufacturing processes for scalable NK cell production, serving autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and pemphigus; it operates primarily in the United States with clinical trials conducted globally. Founded in 2018 and headquartered in San Diego, California, the company recently completed its initial public offering in October 2024, raising gross proceeds of approximately $167 million, and announced a strategic licensing agreement with Otsuka Pharmaceutical in 2024 for AB-201 development in Japan. In late 2024, Artiva initiated dosing in the Phase 1/2 Lukos trial for AB-101 in progressive multifocal leukoencephalopathy (PML) and expanded its manufacturing capacity through a new facility partnership. No subsidiaries or parent companies are reported.
Company News
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
The $13 Million Company Teaching the Immune System to Hunt Cancer
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants